Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness

Pediatric Infectious Disease Journal

Volumn 33, Issue 7, 2014, Pages 703-709

  Ramilo, Octavio ^a   Lagos, Rosanna ^b   Sáez Llorens, Xavier ^c   Suzich, Joann ^d   Wang, C Kathy ^d   Jensen, Kathryn M ^d   Harris, Brian S ^d   Losonsky, Genevieve A ^d   Griffin, M Pamela ^d   Nissen, Michael Desmond ^e   Chuk, Raymond ^e   Zuccone, Rosanna Marietta Lagos ^f   Pizarro, Jose Manuel Pascual Novoa ^g   Sakovets, Ioulia ^g   Villaseca, Katia Gabriela Abarca ^h   Ibanez, Maria Isabel ^h   Fraile, Maria Del Pilar Fernandez ⁱ   Silva, Cecilia ⁱ   Brown, Philip Jeffrey ^j   Lanceley, Sandra ^j   Trenholme, Adrian ^k   McBride Miller, Charissa ^k   Castaño, Elizabeth ^c   Adler Shohet, Felice C ^l   Leiberman, Jay M ^l   O'Donnell, Nan ^l   Ampofo, Kwabena Krow ^m   Stockmann, Chris ^m   Chávez Bueno, Susana ⁿ   Rettig, Sana ⁿ   Meissner, H Cody ^o   Murray, Karen ^o   Park, C Lucy ^p   Bandepalli, Rehka ^p   Powell, Dwight Alden ^q   Sanchez, Pablo José ^r   Mejias, Asuncion ^r   Romero, José Rafael ^s   Simonsen, Kari A ^s   more..

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Centro para Vacunas en Desarrollo Chile   (Chile)

^c Hospital Del Niño Ciudad de Panamá   (United States)

^d MEDIMMUNE   (United States)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

^f HOSPITAL ROBERTO DEL RÍO   (Chile)

^g HOSPITAL PADRE HURTADO   (Chile)

^h PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

ⁱ HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^j PALMERSTON NORTH HOSPITAL   (New Zealand)

^k Division of Medicine Emergency and Integrated Care   (New Zealand)

^l MILLER CHILDREN S HOSPITAL   (United States)

^m UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^o TUFTS MEDICAL CENTER   (United States)

^p UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^q NATIONWIDE CHILDREN S HOSPITAL   (United States)

^r UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^s UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

more..

Author keywords

infant; monoclonal antibody; pediatric; RSV; treatment

Indexed keywords

MOTAVIZUMAB; PLACEBO; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FOLLOW UP; HOSPITALIZATION; HUMAN; INFANT; INTENSIVE CARE UNIT; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; WHEEZING; CLINICAL TRIAL; FEMALE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; ISOLATION AND PURIFICATION; LENGTH OF STAY; LONGITUDINAL STUDY; MALE; NEWBORN; NOSE CAVITY; PATHOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIROLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LENGTH OF STAY; LONGITUDINAL STUDIES; MALE; NASAL CAVITY; PLACEBOS; REAL-TIME POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84902544617     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000240     Document Type: Article

References (16)

1. Boyce TG, Mellen BG, Mitchel EF, Jr., et al. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000;137:865-870.
2. Stockman LJ, Curns AT, Anderson LJ, et al. Respiratory syncytial virus- associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J. 2012;31:5-9.
3. Bourgeois FT, Valim C, McAdam AJ, et al. Relative impact of influenza and respiratory syncytial virus in young children. Pediatrics. 2009;124: e1072-e1080.
4. Bont L, Aalderen WM, Kimpen JL. Long-term consequences of respiratory syncytial virus (RSV) bronchiolitis. Paediatr Respir Rev. 2000;1:221-227.
5. Carroll KN, Hartert TV. The impact of respiratory viral infection on wheezing illnesses and asthma exacerbations. Immunol Allergy Clin North Am. 2008;28:539-561, vIII.
6. Henderson J, Hilliard TN, Sherriff A, et al. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunol. 2005;16:386-392.
7. Martinez FD. Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr Infect Dis J. 2003;22(2 suppl):S76-S82.
8. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012:609-617.
9. Rodriguez WJ, Gruber WC, Groothuis JR, et al. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics. 1997;100:937-942.
10. Sáez-Llorens X, Moreno MT, Ramilo O, et al.; MEDI-493 Study Group. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J. 2004;23:707-712.
11. Malley R, DeVincenzo J, Ramilo O, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis. 1998;178:1555-1561.
12. Lagos R, DeVincenzo JP, Muñoz A, et al. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. Pediatr Infect Dis J. 2009;28:835-837.
13. Hu A, Colella M, Tam JS, et al. Simultaneous detection, subgrouping, and quantitation of respiratory syncytial virus A and B by real-time PCR. J Clin Microbiol. 2003;41:149-154.
14. Carbonell-Estrany X, Simões EA, Dagan R, et al.; Motavizumab Study Group. Motavizumab for prophylaxis of respiratory syncytial virus in high- risk children: a noninferiority trial. Pediatrics. 2010;125: e35-e51.
15. Klassen TP, Sutcliffe T, Watters LK, et al. Dexamethasone in salbutamol- treated inpatients with acute bronchiolitis: a randomized, controlled trial. J Pediatr. 1997;130:191-196.
16. Feltes TF, Sondheimer HM, Tulloh RM, et al.; Motavizumab Cardiac Study Group. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res. 2011;70:186-191.